SIR-Spheres® Y-90 resin microspheres were significantly better tolerated than sorafenib in the safety population:

Significantly fewer and less severe Adverse Events (AE)

Significantly fewer patients with treatment-related AEs

Median treatment-related AEs per patient

Significantly reduced frequency and severity of AEs

Overview of the adverse events in the Safety population

SIR-Spheres Y-90 resin microspheres were safe and well tolerated, with few SIRT associated complications

There was no treatment related radiation hepatitis or radioembolisation induced liver disease.

Vilgrain V et al.  Lancet Oncol 2017; 18: 1624–36.
Bouattour M et al.  Ann Oncol 2017; ESMO 19th WCGIC, Abs. LBA-001.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage